Non-Alcoholic Fatty Liver Disease Prediction and Assessment Techniques

Non-alcoholic fatty liver disease encompasses a spectrum of liver pathology arising from ectopic lipid accumulation in hepatocytes, extending from simple steatosis to steatohepatitis, fibrosis and cirrhosis. Early prediction and accurate assessment of NAFLD are crucial to prevent progression and associated cardiometabolic complications. Traditional diagnosis relies on histological examination, yet non-invasive techniques have rapidly evolved, including serum biomarkers, composite scoring systems, advanced imaging modalities and machine-learning approaches. Serum panels now integrate hepatocellular enzymes with inflammatory and metabolic markers to estimate hepatic fat content and fibrotic stage. Composite indices such as the fatty liver index and the ZJU index combine clinical parameters—body mass index, triglycerides, transaminases and glycaemic measures—to stratify risk in large cohorts. Imaging techniques range from conventional ultrasonography and controlled attenuation parameter by transient elastography to quantitative magnetic resonance proton density fat fraction, offering precise volumetric and compositional assessment. Recent advances in artificial intelligence have enabled automated image analysis and integration of multimodal data for individualised risk prediction. Collectively, these tools enhance population screening, therapeutic monitoring and risk stratification, underlining the global imperative to deploy robust, accessible techniques for NAFLD management.

Research from Nature Portfolio

A foundational model, the ZJU index, was developed in a large Chinese cohort to predict hepatic steatosis using body mass index, fasting plasma glucose, triglycerides and the alanine aminotransferase to aspartate transaminase ratio. The index demonstrated excellent discrimination, with an area under the receiver-operating characteristic curve exceeding 0.82 in validation cohorts and 0.90 when compared with histological steatosis on liver biopsy. This seminal work established a simple, externally validated tool for community screening and has informed the subsequent development of population-specific steatosis scores globally.

Non-Alcoholic Fatty Liver Disease Prediction and Assessment Techniques publication trend

The graph below shows the total number of articles in non-alcoholic fatty liver disease prediction and assessment techniques across all publications each year (not limited to Nature Index journals).

Technical terms

Non-Alcoholic Fatty Liver Disease (NAFLD): A liver disorder characterised by excess lipid accumulation in hepatocytes, unrelated to significant alcohol intake.

Fatty Liver Index (FLI): A composite score combining body mass index, waist circumference, triglycerides and gamma-glutamyltransferase to estimate hepatic steatosis risk.

Magnetic Resonance Proton Density Fat Fraction (MRI-PDFF): A quantitative imaging biomarker that measures the proportion of liver tissue composed of fat with high accuracy.

Soluble Biomarker: A circulating molecule, such as soluble CD46, whose plasma concentration reflects underlying hepatic pathology.

Transient Elastography: A non-invasive ultrasound-based method measuring liver stiffness, used to assess fibrosis and steatosis via controlled attenuation parameter.

References

1. ZJU index: a novel model for predicting nonalcoholic fatty liver disease in a Chinese population. Scientific Reports (2015).
2. Soluble CD46 as a diagnostic marker of hepatic steatosis. EBioMedicine (2024).
3. Combined impact of prediabetes and hepatic steatosis on cardiometabolic outcomes in young adults. Cardiovascular Diabetology (2024).
4. Role of fatty liver index in risk-stratifying comorbid disease outcomes in non-alcoholic fatty liver disease. JHEP Reports (2023).
5. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterology (2006).